2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4502 Association of GLP-1 receptor agonist exposure with relapse and survival after frontline chemoimmunotherapy for diffuse large B-cell lymphoma: A propensity matched trinetx study

Hufsa Khan, MD, Faith Reid, MD2, Patrick Willard, DO3, Carolina Velez-Mejia, MD4, Brian Cassel, Ph.D.5, Victor Yazbeck, MD6
1 Virginia Commonwealth University, Richmond, Virginia, United States
2 Virginia Commonwealth University, Richmond, Virginia, United States
3 Virginia Commonwealth University, Richmond, Virginia, United States
4 Virginia Commonwealth University, Richmond, Virginia, United States
5 Virginia Commonwealth University, Richmond, Virginia, United States
6 Virginia Commonwealth University, Richmond, Virginia, United States

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, with 30–40% of patients developing relapsed disease after frontline chemoimmunotherapy. Patients experiencing early treatment failure (<12 months) have markedly inferior survival and frequently require second-line therapies such as salvage chemotherapy, autologous stem cell transplantation (ASCT), CAR-T therapy, or bispecific antibodies. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) possess anti-inflammatory, metabolic, and immunomodulatory effects with recent data also suggesting potential anti-neoplastic effects; however, this association with relapse and survival after frontline therapy remains unknown.

Methods: We performed a retrospective propensity score-matched cohort study using the TriNetX Global Collaborative Network. Adults with DLBCL treated with frontline R-CHOP or pola-R-CHP were identified and divided by baseline GLP-1RA exposure at the time of diagnosis. Diabetic comparator cohorts included non-GLP-1RA users compared with metformin, SGLT2 (sodium-glucose cotransporter 2) inhibitor, and DPP-4 (dipeptidyl peptidase-4) inhibitor users. The index date was the first administration of frontline therapy. The primary endpoint was a composite of subsequent lymphoma-directed systemic therapy or salvage chemotherapy, ASCT, CAR-T therapy, bispecific antibody therapy, hospice, or all-cause mortality. A 180-day landmark analysis was performed, restricting the cohort to patients who successfully completed frontline therapy within the typical treatment duration. Patients were then followed for the 12 months post-treatment window capturing early treatment failure or relapse associated with the poorest prognosis in DLBCL. 

Results: After matching, 1,125 patients were included for the primary analysis. The primary composite outcome occurred in 102 patients (9.1%) in GLP-1RA exposed versus 184 (16.4%) in the unexposed group (HR 0.44, 95% CI 0.35–0.56; P<0.0001). Similar findings were seen when compared against metformin users in the GLP-1RA exposed group (98/1,033 [9.5%] vs 193/1,033 [18.7%]; HR 0.45, 95% CI 0.35–0.57; P<0.0001). Compared with DPP-4 inhibitors, the analysis also demonstrated significantly fewer events among GLP-1RA users (41/459 [8.9%] vs 97/459 [21.1%]; HR 0.37, 95% CI 0.25–0.53; P<0.0001). No significant differences in the primary endpoint were observed versus SGLT2 inhibitors (HR 0.86, 95% CI 0.73–1.02). Each primary composite component was subsequently analyzed separately. The observed reduction in the composite outcome was primarily attributable to lower utilization of salvage chemotherapy protocols (including platinum-, gemcitabine-, cytarabine-, and etoposide-based salvage regimens such as R-ICE, GemOx, etc.) as well as lower all-cause mortality and hospice utilization. Interestingly, GLP-1RA users compared with SGLT2 inhibitors also had lower bispecific antibody use (1.9% vs 4.3%; HR 0.41, 95% CI 0.25–0.80) whereas SGLT2 inhibitor users had lower rates of subsequent salvage chemotherapy compared with GLP-1RAs (149/837 [17.8%] vs. 188/837 [22.5%]; HR 0.78, 95% CI 0.63–0.97; P=0.016). There were no statistically different rates in cardiovascular outcomes among groups except when comparing SGLT2 inhibitors 256/837 (30.6%) against GLP-1RA users 110/837 (13.1%) (RR 2.33, 95% CI 1.90–2.85; P<0.0001).

Conclusions: Among patients who remained alive and free of treatment failure for 180 days after initiation of frontline therapy, baseline GLP-1RA exposure was associated with a substantially lower risk of subsequent treatment-defined disease failure within the early 12-month relapse window across all comparator cohorts except for the SGLT2 inhibitor group. This suggests that favorable outcomes may reflect mechanisms shared by contemporary cardiometabolic therapies rather than GLP-1RAs alone. Collectively, these findings support the hypothesis that GLP-1RA exposure may be associated with improved outcomes following curative-intent treatment for DLBCL. Further studies investigating differences in lymphoma outcomes between GLP-1RAs versus SGLT2 inhibitors with longer follow-up periods are warranted to determine whether these associations are causal and to further define the potential role of these drugs as a therapeutic adjunct or repurposed strategy for DLBCL relapse and survival.

Hufsa Khan, MD: No relevant conflicts of interest to declare.